Phase 1 Data on MM-398 will be Presented at the ASCO 2012 Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass., Jan. 12, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that Phase 1 results on MM-398, one of its five targeted therapeutic oncology candidates in clinical development, will be presented at the ASCO 2012 Gastrointestinal Cancers Symposium being held January 19 – 21, 2012, in San Francisco, CA.

MM-398

MM-398 is a novel, stable nanotherapeutic encapsulation of irinotecan.  The U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for use in the treatment of pancreatic cancer.  PharmaEngine, Inc. has rights to develop and commercialize MM-398 in Taiwan under the designation PEP02. 

Title: Phase I Study of Biweekly Liposome Irinotecan (PEP02, MM-398) in Metastatic Colorectal Cancer After First-line Oxaliplatin-based Chemotherapy

Poster Session: General Poster Session C: Cancers of the Colon and Rectum

Number: 613

Date/Time: Saturday, January 21st, 2012/ 7:00 AM - 8:00 AM; 12:30 PM - 2:30 PM

Location: Level 1, West Hall

About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com

Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com

SOURCE Merrimack Pharmaceuticals, Inc.



RELATED LINKS
http://www.merrimackpharma.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.